To evaluate whether Trp alleviates MS through the intestinal Fxr pathway, mice were given different treatments starting from 8 weeks of HFD feeding: daily gavage of Gly-MCA (an intestine-specific FXR inhibitor), Trp intervention, and daily gavage of Fex (an intestine-specific FXR activator) in addition to the Trp intervention. The gene discussed is NR1H4; the disease is myeloid sarcoma.